Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

Blood tests are a routine part of your prenatal care. Here's everything you need to know about what you can expect.

By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the ...

* Reactivation phase may be recognized as a variant of immune clearance phase. Dagger; Approximately five copies = 1 IU. ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBV: Hepatitis ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

MZB and B1 B cells have innate sensing properties and are highly sensitive in response to Toll-like receptor (TLR) triggering, which contributes to the clearance of pathogens in the blood by T ...

About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare ... and diffuse large B-cell lymphoma (DLBCL). Based on the encouraging results of ICP-B02 single ...

Hepatitis B and C disproportionately affect certain populations ... This represents people living with positive hepatitis C virus antibody status, including those with chronic hepatitis C, those who ...

The use of injected drugs is the most common way that people contract hepatitis C in the United States and Europe. When you inject drugs, the needle breaks the surface of your skin and comes into ...

A dot plot showing COI for the HBsAg test for all 34 patients who received hepatitis B vaccine 14 days or less before HBsAg testing is shown in Figure 3. There was one patient who had a positive ...